ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02114229
Previous Study | Return to List | Next Study

Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors (SJATRT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02114229
Recruitment Status : Recruiting
First Posted : April 15, 2014
Last Update Posted : March 9, 2018
Sponsor:
Collaborators:
Millennium Pharmaceuticals, Inc.
Takeda Pharmaceuticals U.S.A., Inc.
Information provided by (Responsible Party):
St. Jude Children's Research Hospital

Brief Summary:

This study incorporates alisertib, the small-molecule inhibitor of Aurora A activity, in the treatment of patients younger than 22 years of age. Patients with recurrent or refractory AT/RT or MRT will receive alisertib as a single agent. Patients with newly diagnosed AT/RT will receive alisertib as part of age- and risk-adapted chemotherapy. Radiation therapy will be given to children ≥12 months of age. Patients with AT/RT and concurrent extra-CNS MRT are eligible.

Alisertib will be administered as a single agent on days 1-7 of each 21-day cycle in all recurrent patients enrolled on Stratum A. For the patients on the newly diagnosed strata (B, C or D), alisertib will be administered in sequence with chemotherapy and radiotherapy.

This study has 3 primary strata: (A) children with recurrent/progressive AT/RT or extra-CNS MRT, (B) children < 36 months-old with newly diagnosed AT/RT, (C) children > 36 months old with newly diagnosed AT/RT. Children with concurrent MRT will be treated according to age and risk stratification schemes outlined for strata B and C and will have additional treatment for local control. Children with synchronous AT/RT will be treated with age and CNS risk-appropriate therapy, and also receive surgery and/or radiation therapy for local control of the non-CNS tumor.

PRIMARY OBJECTIVES

  • To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive AT/RT (atypical teratoid rhabdoid tumor in the CNS) (Stratum A1) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population.
  • To estimate the sustained objective response rate and disease stabilization in pediatric patients with recurrent or progressive extra-CNS MRT (malignant rhabdoid tumor outside the CNS) (Stratum A2) treated with alisertib and to determine if the response is sufficient to merit continued investigation of alisertib in this population.
  • To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis with no metastatic disease (Stratum B1) treated with alisertib in sequence with induction and consolidation chemotherapy and radiation therapy (depending on age) and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
  • To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are younger than 36 months of age at diagnosis, with metastatic disease (Stratum B2) treated with alisertib in sequence with induction and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
  • To estimate the 3-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with no metastatic disease and gross total resection or near total resection (Stratum C1) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
  • To estimate the 1-year PFS rate of patients with newly diagnosed AT/RT who are 3 years of age or greater at diagnosis with metastatic or residual disease (Stratum C2) treated with alisertib in sequence with radiation therapy and consolidation chemotherapy and to determine if the rates are sufficient to merit continued investigation of alisertib in this population.
  • To characterize the pharmacokinetics and pharmacodynamics of alisertib in pediatric patients and to relate drug disposition to toxicity.

SECONDARY OBJECTIVES

  • To estimate the duration of objective response and PFS in patients with recurrent/progressive AT/RT and MRT (Strata A1 and A2).
  • To estimate PFS and OS distributions in patients with newly diagnosed AT/RT (Strata B1, B2, B3, C1 and C2).
  • To describe toxicities experienced by patients treated on this trial, specifically any toxicities of alisertib when administered as a single agent or in combination with other therapy over multiple courses and toxicities related to proton or photon radiation therapy.
  • To describe the patterns of local and distant failure in newly diagnosed patients (Strata B1, B2, B3, C1 and C2). Local control relative to primary-site radiation therapy, with criteria for infield, marginal, or distant failure will also be reported descriptively.

Condition or disease Intervention/treatment Phase
Malignant Rhabdoid Tumor Atypical Teratoid Rhabdoid Tumor Drug: alisertib Drug: methotrexate Drug: cisplatin Drug: carboplatin Drug: cyclophosphamide Drug: etoposide Drug: topotecan Drug: vincristine Procedure: Surgical resection Radiation: Radiation therapy Phase 2

  Hide Detailed Description

Detailed Description:

We propose a study with 3 primary treatment strata according to participant's previous treatment, age and presence of extra-CNS disease, with substrata for presence of focal or metastatic disease:

  • STRATUM A - RECURRENT OR PROGRESSIVE DISEASE: Patients < 22 years of age at diagnosis with recurrent or progressive MRT (either CNS and/or extra-CNS) and measurable disease as defined in the protocol.

    • Stratum A1: patients with AT/RT (CNS MRT).
    • Stratum A2: patients with extra-CNS MRT (patients with concurrent progression of AT/RT and MRT are eligible for therapy, but their data will be analyzed separately).
    • Stratum A3: patients with synchronous AT/RT and extra-CNS MRT
  • STRATUM B - NEWLY DIAGNOSED DISEASE IN YOUNG CHILDREN < 36 MONTHS: Patients < 36 months of age at diagnosis of CNS-AT/RT, no prior therapy:

    • Stratum B1: Patients with no metastatic disease (M0).
    • Stratum B2: Patients with metastatic disease (M+) regardless of degree of resection.
    • Stratum B3: Patients for whom CSF by lumbar puncture was not obtained for clinical reasons and have no other evidence of metastatic disease (MX).
  • STRATUM C - NEWLY DIAGNOSED DISEASE IN CHILDREN > 3 YEARS: Patients > 3 years (36 months) of age at diagnosis of AT/RT, no prior therapy:

    • Stratum C1: Patients with gross total (GTR) or near total resection (NTR) defined as <1.5 cm2 of residual tumor, and no metastatic disease.
    • Stratum C2: Patients with metastatic disease (M+) and/or bulky residual tumor >1.5 cm^2.

STRATUM D - SYNCHRONOUS EXTRANEURAL AT/RT and EXTRA-CNS MRT: Treatment will be based on the extent of both CNS and extra-CNS disease. CNS-directed therapy will be given according to Strata B1, B2, C1 or C2 according to age and metastatic status. In addition, patients may receive irradiation according to best clinical management for local control of extra-CNS disease.

  • Stratum D1: Patients < 36 months at time of diagnosis with synchronous AT/RT and extra-CNS MRT and no metastatic CNS disease (M0).
  • Stratum D2: Patients < 36 months at time of diagnosis with synchronous AT/RT and extra- CNS MRT and metastatic CNS disease (M+).
  • Stratum D3: Patients < 36 months at time of diagnosis with synchronous AT/RT and extra-CNS MRT for whom CSF by lumbar puncture was not obtained for clinical reasons and without other evidence of metastatic disease (MX)
  • Stratum D4: Patients ≥ 36 months at time of diagnosis with synchronous extra-CNS MRT with or without metastatic CNS disease regardless of the degree of tumor resection.

Biological parents of participants with ATRT/MRT may consent to and provide a genomic blood specimen for DNA extraction and analysis.

OVERVIEW OF TREATMENT PLAN: Patients with recurrent disease (Stratum A) will receive alisertib as a single agent days 1-7 out of 21 days. Newly diagnosed patients (Strata B, C and D) will receive alisertib in sequence with chemo and radiotherapy. Patients on sub-strata B1 and D1 will receive focal RT once they are >12 months of age. Patients on sub-strata B2 and D2, with disseminated disease will not receive CNS radiation therapy (RT). Patients on sub-strata C1/C2/D4 will receive risk-stratified craniospinal irradiation (CSI) and boost to primary tumor site followed by adjuvant chemotherapy. Patients on sub-strata B3 and D3 will receive therapy similar to sub-strata B2 and D2 and will be considered for local radiotherapy depending on their age, response to therapy, and subsequent metastatic staging. Those patients with concurrent CNS and extra-CNS MRT may undergo irradiation of the extra-CNS MRT according to best clinical management in addition to CNS directed therapy. Alisertib will be administered only to eligible patients under the supervision of the investigator or identified sub-investigator(s).


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 2 Study of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT
Actual Study Start Date : May 14, 2014
Estimated Primary Completion Date : May 2023
Estimated Study Completion Date : May 2027

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: (A) Alisertib alone

Stratum A: Patients with recurrent/progressive AT/RT or extra-CNS malignant rhabdoid tumors (MRT).

Interventions: alisertib, 35 cycles of 3 weeks each (up to 105 weeks). Surgical resection, if indicated.

Drug: alisertib
Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
Procedure: Surgical resection
For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a "second-look" operation is encouraged if and may be performed prior to consolidation therapy.
Other Name: surgical management
Experimental: (B) Alisertib, chemotherapy, radiation therapy

Stratum B: Children < 36 months old with newly diagnosed AT/RT. AT/RT those with synchronous extraneural AT/RT (Stratum D1) may also be treated on this arm.

Interventions:

  • B1 or D1: Induction chemotherapy using methotrexate, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by focal radiation therapy; followed by induction therapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib. Those <12 months who are not ready for focal radiation therapy will receive consolidation chemotherapy using alisertib, cyclophosphamide, carboplatin and etoposide while RT is delayed. Surgical resection, if indicated.
  • B2, B3, D2 or D3: Induction chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by consolidation with topotecan and cyclophosphamide or optional craniospinal irradiation; followed by maintenance alisertib. Surgical resection, if indicated.
Drug: alisertib
Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
Drug: methotrexate
Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
Other Name: MTX
Drug: cisplatin
Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
Other Name: Platinol-AQ
Drug: carboplatin
Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
Other Name: paraplatin
Drug: cyclophosphamide
Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
Other Name: cytoxan
Drug: etoposide

Etoposide will be given 100 mg/m^2 IV infusion.

In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day.

Other Names:
  • VP-16
  • Vepesid
  • Etoposide phosphate (Etopophos)
Drug: topotecan
Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
Other Name: Hycamtin
Drug: vincristine
Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
Other Name: Oncovin
Procedure: Surgical resection
For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a "second-look" operation is encouraged if and may be performed prior to consolidation therapy.
Other Name: surgical management
Radiation: Radiation therapy
The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
Other Names:
  • Craniospinal irradiation (CSI)
  • Radiotherapy
Experimental: (C) Alisertib, chemotherapy, radiation therapy

Stratum C: Children ≥36 months old with newly diagnosed AT/RT.

Participants with synchronous extraneural AT/RT (Stratum D4) will also be treated as those assigned to Stratum C.

Interventions: Craniospinal radiation therapy; followed by consolidation chemotherapy using alisertib, vincristine, cisplatin (or carboplatin), cyclophosphamide; followed by maintenance alisertib, surgical resection, if indicated.

Drug: alisertib
Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
Drug: cisplatin
Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
Other Name: Platinol-AQ
Drug: cyclophosphamide
Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
Other Name: cytoxan
Drug: vincristine
Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
Other Name: Oncovin
Procedure: Surgical resection
For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a "second-look" operation is encouraged if and may be performed prior to consolidation therapy.
Other Name: surgical management
Radiation: Radiation therapy
The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
Other Names:
  • Craniospinal irradiation (CSI)
  • Radiotherapy



Primary Outcome Measures :
  1. Sustained response rate of pediatric participants with recurrent or refractory AT/RT treated with alisertib (stratum A1) [ Time Frame: Within 30 weeks after start of alisertib therapy ]
    Efficacy endpoint: Sustained, objective responses (partial response + complete response) that occur within the first 10 courses (approximately 30 weeks) of treatment. Objective responses must be sustained for an additional 2 courses (approximately 6 weeks) and/or 12-week disease stabilization, as confirmed by MRI in order to be considered a success in the statistical analysis of the efficacy endpoint.

  2. Sustained response rate of pediatric participants with recurrent or refractory MRT treated with alisertib (stratum A2) [ Time Frame: Within 30 weeks after start of alisertib therapy ]
    Efficacy endpoint: Sustained, objective responses (partial response + complete response) that occur within the first 10 courses (approximately 30 weeks) of treatment. Objective responses must be sustained for an additional 2 courses (approximately 6 weeks) and/or 12-week disease stabilization, as confirmed by MRI in order to be considered a success in the statistical analysis of the efficacy endpoint.

  3. 3-year progression free survival rate (stratum B1) [ Time Frame: Up to 3 years after the last enrolled patient starts therapy ]

    Participants with AT/RT who are younger than 36 months of age at diagnosis with no metastatic disease treated with alisertib in sequence with induction and consolidation chemotherapy will be included for this analysis.

    Progression free survival will be measured from the date of diagnosis to the earliest date of disease progression, death, second malignancy, or the date of last follow-up.


  4. 1-year progression free survival rate (stratum B2) [ Time Frame: Up to 1 year after the last enrolled patient starts therapy ]

    Participants with AT/RT who are younger than 36 months of age at diagnosis with metastatic disease treated with alisertib in sequence with induction and consolidation chemotherapy will be included for this analysis.

    Progression free survival will be measured from the date of diagnosis to the earliest date of disease progression, death, second malignancy, or the date of last follow-up.


  5. 3-year progression free survival rate (stratum C1) [ Time Frame: Up to 3 years after the last enrolled patient starts therapy ]
    Participants with AT/RT who are 3 years of age or older at diagnosis with no metastatic disease and gross total resection or near total resection treated with alisertib in sequence with radiation therapy and consolidation chemotherapy will be included for this analysis. Progression free survival will be measured from the date of diagnosis to the earliest date of disease progression, death, second malignancy, or the date of last follow-up.

  6. 1-year progression free survival rate (stratum C2) [ Time Frame: Up to 1-year after the last enrolled patient starts therapy ]
    Participants with AT/RT who are 3 years of age or older at diagnosis with metastatic or residual disease treated with alisertib in sequence with radiation therapy and consolidation chemotherapy will be included for this analysis. Progression free survival will be measured from the date of diagnosis to the earliest date of disease progression, death, second malignancy, or the date of last follow-up

  7. Single dose and steady state pharmacokinetics and pharmacodynamics of alisertib [ Time Frame: Treatment Cycle 1 on days 1 and 7 ]

    Single dose pharmacokinetic studies will be performed on cycle 1 day 1 and serial plasma samples will be collected at: pre-dose and 0.5, 1, 1.5, 4, 6 (± 0.5), 24 (± 4), and 48 (± 6) hours after the first dose.

    Steady-state pharmacokinetic studies will be performed on cycle 1 day 7 and serial plasma samples will be collected at: pre-dose, and 1.5, 4, and 24 (±4) hours after the dose.

    The analysis for the pharmacokinetic primary objective of this study will be conducted using compartmental and noncompartmental approaches. The noncompartmental analysis will provide an estimate of the maximum concentration (Cmax), minimum concentration (Cmin), area under the concentration time curve (AUC), and apparent oral clearance (CL/F). Compartmental analysis will be performed using nonlinear mixed effects modeling and estimated pharmacokinetic parameters may include absorption rate constant (ka), apparent oral clearance (CL/F), and apparent volume of distribution (Vd/F).



Secondary Outcome Measures :
  1. Duration of objective response by stratum A1 and A2 [ Time Frame: At the time of tumor assessment (up to 5 years) ]
    The duration of objective response will be measured from the initial scan documenting complete or partial response to the earlier of documented progression or death on study. Duration of objective response will be censored at the last tumor assessment date for patients without disease progression.

  2. 1-year progression-free survival (PFS) by stratum A1 and A2 [ Time Frame: Up to 5 years after the last enrolled patient starts treatment. ]
    Progression-free survival (PFS) will be measured from the date of initial treatment to the earliest date of disease progression, second malignancy or death. Duration of PFS will be censored at the last tumor assessment date for patients without disease progression.

  3. 5-year Progression-free survival (PFS) rate in patients with newly diagnosed AT/RT (strata B1, B2, B3, C1, C2) [ Time Frame: Up to 5 years after the last enrolled patient starts treatment. ]
    PFS will be measured from the date of diagnosis to the earliest date of disease progression, death, second malignancy, or the date of last follow-up.

  4. 5-year Overall survival (OS) rate in patients with newly diagnosed AT/RT (strata B1, B2, B3, C1, C2) [ Time Frame: Up to 5-years after the last patient starts protocol treatment ]
    OS will be measured from the date of diagnosis to the date of death or date of last contact.

  5. Proportion of local and distant failure in strata B1, B2, B3, C1 and C2 [ Time Frame: Up to 5 years after the last patient starts therapy ]
    Local control relative to primary site radiotherapy, with criteria for infield, marginal or distant failure will be reported descriptively. Patterns of failure and sites of progression of disease will be described separately in each study stratum. Summary statistics of follow-up time and corresponding 95% confidence intervals will be provided. Point estimates of percentages of local and distant failures and exact confidence interval estimates will be constructed as well.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA for Patients on All Strata EXCEPT Stratum P

  • Patients must be < 22 years of age at time of diagnosis (e.g., eligible until 22nd birthday).
  • Histologic diagnosis of AT/RT or MRT as documented by the institutional pathologist with loss of INI1 or BRG1 expression in tumor cells confirmed by immunohistochemistry, or by molecular confirmation of tumor-specific biallelic SMARCB1/SMARCA4 loss/mutation if INI1/BRG1 immunohistochemistry is not available. For Stratum A participants, histologic confirmation of the diagnosis of AT/RT or MRT may be from the original diagnosis or at the time of recurrence/progression.
  • Patients must have adequate organ function (bone marrow, renal, liver), as defined in the protocol.
  • Female patients who are at least 10-years-old or are post-menarchal must have a negative serum or urine pregnancy test prior to enrollment.
  • Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence during study treatment and 12 months after the last dose of alisertib.

Inclusion Criteria for Stratum A Participants:

  • Patients with recurrent or progressive AT/RT/MRT (either CNS and/or extra-CNS) with radiographically measurable disease as defined by at least 1 lesion that can be measured in 2 dimensions or with tumor cells present in the CSF taken within 2 weeks prior to enrollment.
  • Performance status defined by Karnofsky or Lansky > 60 (except for patients with posterior fossa syndrome). Use Karnofsky for patients > 16 years and Lansky for patients < 16 years. Note: Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered to be ambulatory for the purpose of assessing the performance score.
  • Patient has fully recovered from the acute toxic effects of chemotherapy, immunotherapy, or radiation therapy prior to entering this study:

    • Myelosuppressive chemotherapy: Patient has not received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (4 and 6 weeks if prior temozolomide and nitrosourea, respectively).
    • Hematopoietic growth factors: At least 7 days must have elapsed since the completion of therapy with a growth factor. At least 14 days must have elapsed after receiving pegfilgrastim.
    • Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur.
    • Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody (see Appendix I).
    • Radiation therapy: at least 3 months must have elapsed since any irradiation unless measurable disease progression occurs at a site separate from the irradiated area and the patient has recovered from toxicities associated with radiation therapy.
  • Patients with progressive synchronous/metachronous AT/RT and MRT will be eligible for stratum A3.
  • Patients may not have previously received alisertib.
  • Live expectancy >8 weeks.
  • Stable neurologic deficits on a stable dose of corticosteroids (if applicable) for at least 1 week before study enrollment.

Inclusion Criteria for Strata B or C Participants:

  • Patients with newly diagnosed AT/RT.
  • Performance status defined by Karnofsky or Lansky > 30 (except for patients with posterior fossa syndrome). Other requirements of performance evaluation are the same as for Stratum A participants.
  • No previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroids.
  • Patients must begin treatment as outlined in the protocol within 42 days of definitive surgery (day of surgery is day 0; definitive surgery includes last surgery to resect residual tumor).

Inclusion Criteria for Stratum D Participants:

  • Patients with newly diagnosed AT/RT and synchronous extra-CNS MRT.
  • Performance status defined by Karnofsky or Lansky > 30 (except for patients with posterior fossa syndrome). Other requirements of performance evaluation are the same as for Stratum A participants.
  • No previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroids.
  • Patients must begin treatment within 42 days of definitive surgery (day of surgery is day 0; definitive surgery includes repeat surgeries to resect residual tumor).

Inclusion Criteria for Stratum P Participants:

  • Biological parent of patient enrolling on the protocol (SJATRT) will be assigned to Stratum P.

EXCLUSION CRITERIA for All Strata Except Stratum P:

  • Clinically significant medical disorders that could compromise the ability to tolerate protocol therapy or that would interfere with the study procedures or results history.
  • Presence of an active, uncontrolled infection.
  • Known history of uncontrolled sleep apnea syndrome or other conditions that could result in excessive daytime sleepiness, such as severe chronic obstructive pulmonary disease or a requirement for supplemental oxygen.
  • Requirement for constant administration of proton-pump inhibitor, H2 antagonist, or pancreatic enzymes. Intermittent uses of antacids or H2 antagonists are allowed while patients are on dexamethasone as described in the protocol.
  • Inability to comply with the safety monitoring requirements of the study, as judged by the investigator.
  • Female participants of childbearing potential cannot be pregnant or breast-feeding.
  • Patients who are receiving other investigational drugs 14 or fewer days before enrollment.
  • Treatment with clinically significant enzyme inducers, such as the enzyme-inducing antiepileptic drugs phenytoin, carbamazepine or phenobarbital, or with rifampin, rifabutin, rifapentine, or St. John's wort within 7 days prior to initiation of alisertib.
  • Known gastrointestinal disease or procedures that could interfere with the oral absorption or tolerance of alisertib. Examples include, but are not limited to partial gastrectomy, history of small intestine surgery, and celiac disease.
  • Myocardial infarction within 6 months prior to enrollment or New York Heart Association Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. If for some reason an electrocardiogram is obtained before study enrollment, any abnormalities detected should be documented as clinically irrelevant.
  • Other severe acute or chronic medical or psychiatric condition, including uncontrolled diabetes, malabsorption, resection of the pancreas or upper small-bowel, or requirement for pancreatic enzymes, any condition that would modify the absorption of oral medications in the small bowel or any laboratory abnormality that may increase the risk associated with study participation or investigational product administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for enrollment in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02114229


Contacts
Contact: Tabatha E. Doyle, RN 901-595-2544 tabatha.doyle@stjude.org

Locations
United States, California
Children's Hospital of Los Angeles Withdrawn
Los Angeles, California, United States, 90027
Lucille Packard Children's Hospital at Stanford University Medical Center Recruiting
Palo Alto, California, United States, 94304
Contact: Sonia Partap, MD    650-723-0993    spartap@stanford.edu   
Principal Investigator: Sonia Partap, MD         
Rady Children's Hospital Recruiting
San Diego, California, United States, 92123
Contact: John Crawford, MD, MS    858-576-1700    jcrawford@rchsd.org   
Principal Investigator: John Crawford, MD, MS         
United States, Colorado
Children's Hospital Colorado Recruiting
Aurora, Colorado, United States, 80045
Contact: Kathleen Dorris, MD    720-777-6672    kathleen.dorris@childrenscolorado.org   
Principal Investigator: Kathleen Dorris, MD         
United States, District of Columbia
Children's National Medical Center Recruiting
Washington, District of Columbia, United States, 20010
Contact: Lindsay B. Kilburn, MD    202-476-2800    lkilburn@childrensnational.org   
Principal Investigator: Lindsay B. Kilburn, MD         
United States, Florida
UF Cancer Center at Orlando Health Recruiting
Orlando, Florida, United States, 32806
Contact: Amy A. Smith, MD    321-841-7246    amy.smith@orlandohealth.com   
Principal Investigator: Amy A. Smith, MD         
United States, Georgia
Children's Healthcare of Atlanta Recruiting
Atlanta, Georgia, United States, 30322
Contact: Sindy Moon    404-785-1441    cindy.moon@choa.org   
Contact: Jaclyn Smith    404-785-0692    jaclyn.smith@choa.org   
Principal Investigator: Dolly Aguilera, MD         
United States, Minnesota
Children's Hospital and Clinics of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55102
Contact: Anne Bendel, MD    651-220-6732    anne.bendel@childrensmn.org   
Principal Investigator: Anne Bendel, MD         
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Tabatha E. Doyle, RN    901-595-2544    tabatha.doyle@stjude.org   
Principal Investigator: Alberto Broniscer, MD         
United States, Texas
Texas Children's Hospital Recruiting
Houston, Texas, United States, 77030
Contact: Patricia Baxter, MD    832-824-1000    pabaxter@txch.org   
Principal Investigator: Patricia Baxter, MD         
United States, Washington
Seattle Children's Hospital Recruiting
Seattle, Washington, United States, 98105
Contact: Sarah Leary, MD    866-987-2000    sarah.leary@seattlechildrens.org   
Principal Investigator: Sarah Leary, MD         
Sponsors and Collaborators
St. Jude Children's Research Hospital
Millennium Pharmaceuticals, Inc.
Takeda Pharmaceuticals U.S.A., Inc.
Investigators
Principal Investigator: Alberto Broniscer, MD St. Jude Children's Research Hospital

Additional Information:
Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT02114229     History of Changes
Other Study ID Numbers: ATRT
NCI-2014-00901 ( Registry Identifier: NCI Clinical Trial Registration Program )
First Posted: April 15, 2014    Key Record Dates
Last Update Posted: March 9, 2018
Last Verified: March 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by St. Jude Children's Research Hospital:
Alisertib
MLN8237
AT/RT
MRT

Additional relevant MeSH terms:
Neoplasms
Rhabdoid Tumor
Teratoma
Neoplasms, Complex and Mixed
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Etoposide phosphate
Cisplatin
Cyclophosphamide
Carboplatin
Methotrexate
Etoposide
Vincristine
Topotecan
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Antimetabolites, Antineoplastic
Antimetabolites
Dermatologic Agents
Enzyme Inhibitors